With three relatively new drugs, plus a busy pipeline in both systemic lupus erythematosus (SLE) and lupus nephritis (LN), the
But US neurologists also express frustration with current lack of therapies Neurologists in the U.S. are optimistic about the potential
To gauge the impact and evolving landscape of HS treatment post-secukinumab approval, Spherix Global Insights conducted research with more than
A chart review completed by Spherix Global Insights shows that more nephrologists are using SGLT2 inhibitors to treat patients with
Despite the expanded armamentarium, Cosentyx has not impacted dermatologists’ perceived unmet need for new HS treatment options, according to Spherix
News pertaining to biosimilars came at a fast and furious pace in 2023. This was the year of the big
According to results of a recent survey, more than 80% of U.S.-based neurologists agreed that a major unmet need in
Analysis of 1,052 chronic kidney disease non-dialysis patient charts reveals continuous growth in SGLT2 inhibitor use and expanding opportunities for
According to Spherix Global Insights’ first market landscape study on Huntington’s disease, neurologists are staking their hopes on gene therapy.
But Spherix surveys across 2023 may not reflect recent setbacks in clinical trials More than one-third of neurologists in the
Ophthalmologists’ reservations about using Syfovre in Geographic Atrophy are more limited to “new start” patients, according to Spherix Global Insights.
Efficacy and safety of pipeline multiple sclerosis assets viewed as increasingly important characteristics, according to Spherix Global Insights. [Exton PA,
